PCI-34051
HDAC8 inhibitor / PCI-34051 is a potent and selective HDAC8 inhibitor (IC50=10 nM) with greater than 200-fold selectivity over HDACs 1, 2, 3, 6, 10.1 Unlike broad-spectrum HDAC inhibitors, it does not cause detectable histone or tubulin acetylation.1 Studies employing PCI-34051 showed that HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine.2 It is a very useful tool for exploring the role of HDAC8 in cellular function.3-6
Biochemicals & reagents
950762-95-5
1 Balasubramanian et al. (2008), A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas; Leukemia 22 1026 2 Aramsangtienchai et al. (2016), HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine; ACS Chem. Biol. 11 2685 3 Dasgupta et al. (2016), HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesion-dependent Transcription in MCF7 Cancer Cells; J. Biol. Chem. 291 12761 4 Ha et al. (2016), Inhibition of Interleukin 1ß (IL-1ß) Expression by Anthrax Lethal Toxin (LeTx) is Reversed by Histone Deacetylase 8 (HDAC8) Inhibition in Murine Macrophages; J. Biol. Chem. 291 8745 5 Fukuda et al. (2024), Inhibition of HDAC8 Reduces the Proliferation of Adult Neural Stem Cells in the Subventricular Zone; Int. J. Mol. Sci. 25 2540 6 Mormino et al. (2024), Histone-deacetylase 8 drives the immune response and the growth of glioma; Glia 69 2682
-20°C
TARGET: Protein deacetylase -- PATHWAY: Chromatin; Posttranslational modification; Mitochondrial function -- RESEARCH AREA: Epigenetics; Stem cells -- DISEASE AREA: Cancer